Literature DB >> 10832978

The role of osteopontin in the development of granulomatous lesions in lung.

S Chiba1, M M Rashid, H Okamoto, H Shiraiwa, S Kon, M Maeda, M Murakami, M Inobe, A Kitabatake, A F Chambers, T Uede.   

Abstract

Osteopontin (OPN) has been shown to be expressed by cells in granulomas of various origins, but whether it plays a functional role in granuloma formation is not known. Here we used a cardiomyopathic hamster (TO2) model, to test the hypothesis that OPN contributes functionally to granuloma development. We immunized cardiomyopathic and normal hamsters by subcutaneous injection of bovine serum albumin in complete Freund's adjuvant, and assessed various tissues for both OPN RNA expression and granuloma formation. Cardiomyopathic hamsters expressed OPN, and formed granulomatous lesions, in heart tissue in both immunized and untreated animals. In addition, immunization induced expression of OPN in lung and lymph nodes of cardiomyopathic (but not normal) hamsters, and also induced granuloma formation in these organs. To test whether OPN expression could play a functional role in inducing granulomas, we produced an adenoviral vector containing the murine OPN gene, and introduced this vector intratracheally into the lungs of normal hamsters. The OPN-containing vector, but not the control vector, induced pulmonary granuloma formation. These studies provided direct in vivo evidence that OPN can contribute functionally to the formation of granulomatous lesions, and suggest that OPN expression may be a common factor involved in formation of granulomas of various origin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832978     DOI: 10.1111/j.1348-0421.2000.tb02501.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  7 in total

1.  Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells.

Authors:  Yoshinobu Koguchi; Kazuyoshi Kawakami; Shigeyuki Kon; Tatsuya Segawa; Masahiro Maeda; Toshimitsu Uede; Atsushi Saito
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis.

Authors:  Nobuchika Yamamoto; Fumihiko Sakai; Shigeyuki Kon; Junko Morimoto; Chiemi Kimura; Harumi Yamazaki; Ikuko Okazaki; Nobuo Seki; Takashi Fujii; Toshimitsu Uede
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

3.  Effect of osteopontin alleles on beta-glucan-induced granuloma formation in the mouse liver.

Authors:  Kumiko Tanaka; Junko Morimoto; Shigeyuki Kon; Chiemi Kimura; Manabu Inobe; Hongyan Diao; Gregor Hirschfeld; Johannes M Weiss; Toshimitsu Uede
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

Review 4.  Osteopontin and cardiovascular system.

Authors:  Hiroshi Okamoto
Journal:  Mol Cell Biochem       Date:  2006-11-30       Impact factor: 3.842

5.  Time course of lung retention and toxicity of inhaled particles: short-term exposure to nano-Ceria.

Authors:  Jana Keller; Wendel Wohlleben; Lan Ma-Hock; Volker Strauss; Sibylle Gröters; Karin Küttler; Karin Wiench; Christiane Herden; Günter Oberdörster; Bennard van Ravenzwaay; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2014-10-02       Impact factor: 5.153

6.  Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology.

Authors:  Terianne M Wong; Sandhya Boyapalle; Viviana Sampayo; Huy D Nguyen; Raminder Bedi; Siddharth G Kamath; Martin L Moore; Subhra Mohapatra; Shyam S Mohapatra
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

7.  Application of short-term inhalation studies to assess the inhalation toxicity of nanomaterials.

Authors:  Robert Landsiedel; Lan Ma-Hock; Thomas Hofmann; Martin Wiemann; Volker Strauss; Silke Treumann; Wendel Wohlleben; Sibylle Gröters; Karin Wiench; Bennard van Ravenzwaay
Journal:  Part Fibre Toxicol       Date:  2014-04-04       Impact factor: 9.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.